Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS
Launched by NATIONAL UNIVERSITY HEALTH SYSTEM, SINGAPORE · Sep 26, 2014
Trial Information
Current as of August 19, 2025
Terminated
Keywords
ClinConnect Summary
Current best practices for management of severe ARDS include lung protective ventilation and nursing in the prone position. However, the best lung protective strategy is not currently established and using smaller ventilation volumes than standard lung protective ventilation suggest lung recovery is improved.
Application of smaller ventilation volumes requires extracorporeal carbon dioxide removal, using a device similar to a dialysis to remove carbon dioxide directly from the blood. One such device in the Prismalung, it removes blood through a catheter, much like a dialysis catheter, pump...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admitted to MICU with respiratory failure and intubated
- • ARDS criteria per Berlin definition
- • PaO2:FiO2 ratio ≤ 200 mmHg for \> 6 hours with FiO2 ≥0.5
- • Expected to require mechanical ventilation for \>48 hours
- • Reversible disease
- Exclusion Criteria:
- • Anticoagulation contraindicated
- • Proven HIT
- • Unable to obtain central venous access
- • Refractory hypoxia (PaO2:FiO2 ≤80 after recruitment and proning) or other indication for ECMO
- • Home oxygen use
- • Severe COPD
- • Interstitial lung disease
- • \> 7 days of mechanical ventilation
- • Immunocompromised patient (bone marrow, untreated HIV, PJP)
- • Advanced malignancy with life expectancy ≤ 6months
About National University Health System, Singapore
The National University Health System (NUHS) in Singapore is a leading academic health system dedicated to advancing healthcare through innovative research, education, and patient care. Comprising a network of hospitals, specialty centers, and primary care clinics, NUHS integrates clinical practice with cutting-edge research and medical education, fostering collaboration among healthcare professionals, researchers, and educators. As a prominent clinical trial sponsor, NUHS is committed to conducting rigorous and ethical research to develop new treatments and improve patient outcomes, while also training the next generation of healthcare leaders in a dynamic and multidisciplinary environment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Singapore, , Singapore
Patients applied
Trial Officials
Matthew E Cove, MBChB
Principal Investigator
National University Health System
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials